WO2016126217A1 - Stable pharmaceutical combination containing benzydamine - Google Patents

Stable pharmaceutical combination containing benzydamine Download PDF

Info

Publication number
WO2016126217A1
WO2016126217A1 PCT/TR2015/000038 TR2015000038W WO2016126217A1 WO 2016126217 A1 WO2016126217 A1 WO 2016126217A1 TR 2015000038 W TR2015000038 W TR 2015000038W WO 2016126217 A1 WO2016126217 A1 WO 2016126217A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
zinc
benzydamine
quaternary ammonium
Prior art date
Application number
PCT/TR2015/000038
Other languages
French (fr)
Inventor
Ersin Yildirim
Murat Muhibbi IŞIK
Sandeep Jain
Asiye Sezgin
Özlem KARAER
Tolga Ramazan KARASU
Koray YILMAZ
Original Assignee
Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş. filed Critical Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş.
Priority to PCT/TR2015/000038 priority Critical patent/WO2016126217A1/en
Publication of WO2016126217A1 publication Critical patent/WO2016126217A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the stable pharmaceutical compositions containing benzydamine hydrochloride as an anti-inflammatory agent, an quaternary ammonium compound of antiseptics, a local anesthetic agent and optionally zinc salt.
  • sore throats are caused cold and viruses. Some sore throats can be caused by infection by bacteria. Antibiotics is rarely required in some cases. Viral sore throats, on the other hand, do not respond to antibiotics, and therefore management of the symptoms is required until the virus has been eliminated by the body.
  • Sore throat products are available as lozenges, sprays, gargles, and, most recently, pain strips that are applied directly to the tongue, providing immediate pain relief.
  • These agents usually contain anesthetics, such as benzocaine and dyclonine hydrochloride, which provide temporary relief.
  • Other products available contain local antiseptics, such as cetylpyridinium chloride, hexylresorcinol, and/or menthol or camphor. Some products also may contain phenol.
  • Benzydamine is a locally acting anesthetic and analgesic drug. It is used for gingivitis, stomatitis, glossitis apthous ulcers, dental surgery and oral ulceration due to radiation therapy, pharyngitis, tonsillitis, post tonsillectomy radiation or intubation mucositis.
  • Benzydamine has analgesic, antipyretic, and anti-inflammatory effects.
  • Benzydamine hydrochloride is painkiller medicine utilized to relieve mild to moderate pain and inflammation in a particular area. If it directly applied to the affected area, it can be very effective.
  • Benzydamine also works by preventing the formation of prostaglandins.
  • topically applied benzydamine is effective in attenuating a variety of inflammatory conditions including oral mucositis induced by antineoplastic radiation or chemotherapy.
  • Antiseptics can be used for handwashing, pre-operative skin disinfection, mucous membrane disinfection, preventing and treating infected wounds and burns, treating mouth and throat infections.
  • Antiseptics can be classified according to their chemical structure. Commonly used antiseptic groups are alcohols, quaternary ammonium compounds, chlorhexidine and other diguanides, antibacterial dyes, chlorine and hypochlorites, inorganic iodine compounds, metals, peroxides and permanganates, halogenated phenol derivatives and quinolone derivatives. Cetylpyridinium chloride is a member of quaternary ammonium compounds.
  • Cetylpyridinium chemical name is 1-Hexadecylpyridinium, is a cationic bactericidal surfactant used as a topical antiseptic for skin.
  • Cetylpyridinium chloride can be purchased in two forms: cetylpyridinium chloride and cetylpyridinium chloride monohydrate. Cetylpyridinium chloride is commonly used in oral rinses for cleaning mouth and treating throat or mouth infections and teething problems.
  • Cetylpyridinium chloride is a cationic quaternary ammonium compound that is known to have antibacterial properties and helps fight plaque and gingivitis. Cetylpyridinium chloride has a combination of antibacterial and anti-fungal activity.
  • Cetylpyridinium is a topical antiseptic for skin, wounds, mucous membranes, instruments. It is used in solutions or lozenges for the treatment of minor infections of the mouth and throat depending antiseptic properties.
  • Local anesthetics have been used in the aim of having a local analgesic effect, including absence of pain sensation for many years. Local anesthetics can be used for acute and chronic pain, also industry of surgery, podiatry and dentistry.
  • Lidocaine chemical name is (1 E)-2-(Diethylamino)-N-(2,6-dimethylphenyl)ethanimidic acid, is also called xylocaine or lignocaine.
  • Zinc is a metal that is called an "essential trace element" because very small amounts of zinc are necessary for human health. It can be used for boosting the immune system, treating the common cold and recurrent ear infections, and preventing lower respiratory infections. Also zinc is used for malaria and other diseases caused by parasites.
  • Zinc salts is applied to the skin for treating acne, aging skin, herpes simplex infections, and to speed wound healing.
  • Zinc preparation can be sprayed in the nostrils for treating the common cold.
  • EP 0812193 relates to the oral hygiene compositions containing an anti-inflammatory agent; benzydamine and a anti-microbial agent; cetyl pyridinium chloride and having improved antimicrobial activity.
  • composition of the invention may contain benzydamine and cetyl pyridinium chloride in the ratio (by weight) of from 10:1 to 1 :10.
  • EP0759739 describes a method of adding chemotherapeutic preparations including cetylpyridinium chloride and lidocaine to dental containing several bundles comprising multiple fibres.
  • EP2570123 there is provided the use of one or more anti-bacterial compounds including cetylpyridinium chloride and lidocaine for the preparation of a medicament wherein the one or more anti-bacterial compounds exhibits an anaesthetic effect.
  • the present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1.) good stability properties, 2.) controlling the release of the active ingredient according to desired therapeutical needs, and finally 3.) simple and also competitive manufacturing process.
  • the major subject of the present invention is to provide a formulation which has resistant against physical and environmental conditions and also have a high bioavailability.
  • composition characterized in that it comprises:
  • benzydamine, lidocaine and also a zinc salt may be effectively combined with cetylpyridinium chloride, comparing with single activity of benzydamine and with an enhancement of the activity of cetylpyridinium chloride and other compounds, so as to provide an effective antiseptic, anti-inflammatory and analgesic treatment.
  • cetylpyridinium chloride comparing with single activity of benzydamine and with an enhancement of the activity of cetylpyridinium chloride and other compounds, so as to provide an effective antiseptic, anti-inflammatory and analgesic treatment.
  • This invention is related to a pharmaceutical product that contains a local anesthetic called lidocaine or its salts, which relieves pain and irritation; and nonsteroidal anti-inflammatory agent called benzydamine or its salts in anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth; and an antiseptic called cetylpyridinium chloride, which kills bacteria and helps prevent infection.
  • a local anesthetic called lidocaine or its salts
  • benzydamine or its salts in anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth
  • an antiseptic called cetylpyridinium chloride
  • a preferred embodiment according to the present invention relates to a pharmaceutical composition, characterized in that it comprises:
  • a) active ingredient selected from nonsteroidal anti-inflammatory agents is benzydamine hydrochloride,
  • active ingredient selected from quaternary ammonium compound of antiseptics is cetylpyridinium chloride
  • active ingredient selected from local anesthetic agents is lidocaine
  • Benzydamine may be used as a pharmaceutically acceptable salt thereof, for example benzydamine hydrochloride.
  • Cetylpyridinium may be used as a pharmaceutically acceptable salt thereof, for example cetylpyridinium chloride.
  • zinc means a compound including, but not limited to; zinc,zinc acetate, zinc bromide, zinc caprylate, zinc carbonate, zinc chloride, zinc citrate, zinc formate, zinc hexafluorosilicate, zinc iodate, zinc iodide, zinc iodide-starch, zinc lactate, zinc nitrate, zinc oleate, zinc oxalate, zinc oxide, calamine (zinc oxide with a small proportion of ferric oxide), zinc p-phenolsulfonate, zinc propionate, zinc salicylate, zinc silicate, zinc stearate, zinc sulfate, zinc sulfide, zinc tarmate, zinc tartrate, zinc valerate, zinc ethylenebis(dithiocarbamate), poly(zinc acryfate) or a combination thereof and their pharmaceutically acceptable salts.
  • the formulation according to the present invention may be in the form of lozenge and other solid oral dosage forms or liquid oral dosage forms.
  • the preferred dosage form according to the present invention is the solid dosage form, preferably a tablet or lozenge form.
  • Lozenges are the most commonly used OTC products for the treatment of sore throat pain. There are 3 main types: lozenges with a weak topical anesthetic, lozenges with menthol, and unmeditated lozenges.
  • composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s).
  • Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, binders, lubricants, glidants, sweeteners, aromatic agents, preservatives, coloring agents, and the mixtures thereof, to facilitate the physical formulation of various dosage forms like orally disintegrating tablets, chewable tablets and suspensions (including dry powders or granules for suspension).
  • a preferred embodiment according to the present invention provides a method for preparing pharmaceutical granules in wet granulation, comprising the steps of
  • Benzydamine hydrochloride an quaternary ammonium compound of antiseptics, a local anesthetic agent, optionally a zinc salt and excipients are mixed with a binder solution comprising PVP, ethanol or water or a combination thereof,
  • a further preferred embodiment according to the present invention provides a method for preparing pharmaceutical granules in wet granulation, comprising the steps of
  • benzydamine HCI, cetylpyridinium chloride, lidocaine and optionally a zinc salt and excipients are mixed with a binder solution comprising PVP, ethanol or water or a combination thereof, b. after wet granulation process, next steps are fluid bed drying, sieving and finally blend is obtained,
  • compositions of this invention may be used in therapy or as a prophylatic against microbial infections accompanied by irritation, such as skin infections.
  • composition can be used for oral application: as an antiseptic, anti-inflammatory and analgesic treatment of gums, mouth and throat, especially for treatment of plaque, gingivitis and periodontitis, denture irritation. It is useful for treating sore or bacteria infected throat, cough-irritated sore throat, and other oral ailments wherein the source of irritation is partly or wholly derived from microbial infection.
  • pharyngitis eg following tonsillectomy
  • aphthous ulcers e.g following tonsillectomy
  • aspecific odontostomatoligic affections e.g following glossitis and stomatitis
  • teeting troubles pain and may be used before and/or after dental extractions.
  • Intra-granular powders are weighed and mixed, and optionally a zinc salt is added in a pharmaceutically effective amount.
  • Binder solution is prepared by adding PVP K30 to water, 3. Dry mix of Step 1 is granulated with binder of step 2 and granules are dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the preparation of stable pharmaceutical compositions comprising benzydamine hydrochloride as an anti-inflammatory agent, cetylpyridinium as an quaternary ammonium compound of antiseptics, lidocaine hydrochloride as a local anesthetic agent and optionally a zinc salt.

Description

STABLE PHARMACEUTICAL COMBINATION CONTAINING BENZYDAMINE
Field of invention
The present invention relates to the stable pharmaceutical compositions containing benzydamine hydrochloride as an anti-inflammatory agent, an quaternary ammonium compound of antiseptics, a local anesthetic agent and optionally zinc salt.
Background of the invention
Most sore throats are caused cold and viruses. Some sore throats can be caused by infection by bacteria. Antibiotics is rarely required in some cases. Viral sore throats, on the other hand, do not respond to antibiotics, and therefore management of the symptoms is required until the virus has been eliminated by the body.
Sore throat products are available as lozenges, sprays, gargles, and, most recently, pain strips that are applied directly to the tongue, providing immediate pain relief. These agents usually contain anesthetics, such as benzocaine and dyclonine hydrochloride, which provide temporary relief. Other products available contain local antiseptics, such as cetylpyridinium chloride, hexylresorcinol, and/or menthol or camphor. Some products also may contain phenol.
Benzydamine is a locally acting anesthetic and analgesic drug. It is used for gingivitis, stomatitis, glossitis apthous ulcers, dental surgery and oral ulceration due to radiation therapy, pharyngitis, tonsillitis, post tonsillectomy radiation or intubation mucositis.
Benzydamine has analgesic, antipyretic, and anti-inflammatory effects. Benzydamine hydrochloride is painkiller medicine utilized to relieve mild to moderate pain and inflammation in a particular area. If it directly applied to the affected area, it can be very effective. Benzydamine also works by preventing the formation of prostaglandins.
It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of rheumatic diseases and inflammation of the mouth and throat.
Several clinical studies suggest that topically applied benzydamine is effective in attenuating a variety of inflammatory conditions including oral mucositis induced by antineoplastic radiation or chemotherapy.
The preparation of benzydamine is described in US 3318905. Chemical name is 3-[(1-Benzyl- 1H-indazol-3-yl)oxy]-N,N-dimethyl-1-propanamine. There have been proposals to use benzydamine in mouth washes in many sources.
l Antiseptics can be used for handwashing, pre-operative skin disinfection, mucous membrane disinfection, preventing and treating infected wounds and burns, treating mouth and throat infections.
Antiseptics can be classified according to their chemical structure. Commonly used antiseptic groups are alcohols, quaternary ammonium compounds, chlorhexidine and other diguanides, antibacterial dyes, chlorine and hypochlorites, inorganic iodine compounds, metals, peroxides and permanganates, halogenated phenol derivatives and quinolone derivatives. Cetylpyridinium chloride is a member of quaternary ammonium compounds.
Cetylpyridinium, chemical name is 1-Hexadecylpyridinium, is a cationic bactericidal surfactant used as a topical antiseptic for skin. Cetylpyridinium chloride can be purchased in two forms: cetylpyridinium chloride and cetylpyridinium chloride monohydrate. Cetylpyridinium chloride is commonly used in oral rinses for cleaning mouth and treating throat or mouth infections and teething problems.
Cetylpyridinium chloride is a cationic quaternary ammonium compound that is known to have antibacterial properties and helps fight plaque and gingivitis. Cetylpyridinium chloride has a combination of antibacterial and anti-fungal activity.
Cetylpyridinium is a topical antiseptic for skin, wounds, mucous membranes, instruments. It is used in solutions or lozenges for the treatment of minor infections of the mouth and throat depending antiseptic properties.
Figure imgf000003_0001
Benzydamine Cetylpyridinium Lidocaine
Local anesthetics have been used in the aim of having a local analgesic effect, including absence of pain sensation for many years. Local anesthetics can be used for acute and chronic pain, also industry of surgery, podiatry and dentistry.
Lidocaine, chemical name is (1 E)-2-(Diethylamino)-N-(2,6-dimethylphenyl)ethanimidic acid, is also called xylocaine or lignocaine.
Zinc is a metal that is called an "essential trace element" because very small amounts of zinc are necessary for human health. It can be used for boosting the immune system, treating the common cold and recurrent ear infections, and preventing lower respiratory infections. Also zinc is used for malaria and other diseases caused by parasites.
Zinc salts is applied to the skin for treating acne, aging skin, herpes simplex infections, and to speed wound healing. Zinc preparation can be sprayed in the nostrils for treating the common cold.
EP 0812193 relates to the oral hygiene compositions containing an anti-inflammatory agent; benzydamine and a anti-microbial agent; cetyl pyridinium chloride and having improved antimicrobial activity. This document is relevant to provide an effective antiseptic, anti-inflammatory and analgesic treatment for microbial infections in suitable forms of the gum, mouth and throat. According to this document, composition of the invention may contain benzydamine and cetyl pyridinium chloride in the ratio (by weight) of from 10:1 to 1 :10.
EP0759739 describes a method of adding chemotherapeutic preparations including cetylpyridinium chloride and lidocaine to dental containing several bundles comprising multiple fibres.
According to EP2570123, there is provided the use of one or more anti-bacterial compounds including cetylpyridinium chloride and lidocaine for the preparation of a medicament wherein the one or more anti-bacterial compounds exhibits an anaesthetic effect.
Summary of the invention
The present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1.) good stability properties, 2.) controlling the release of the active ingredient according to desired therapeutical needs, and finally 3.) simple and also competitive manufacturing process.
The major subject of the present invention is to provide a formulation which has resistant against physical and environmental conditions and also have a high bioavailability.
Pharmaceutical composition, characterized in that it comprises:
a) Benzydamine or pharmaceutical acceptable salt thereof as nonsteroidal antiinflammatory agent,
b) a quaternary ammonium compound of antiseptic,
c) a local anesthetic agent,
d) optionally a zinc salt,
We have now surprisingly found that benzydamine, lidocaine and also a zinc salt may be effectively combined with cetylpyridinium chloride, comparing with single activity of benzydamine and with an enhancement of the activity of cetylpyridinium chloride and other compounds, so as to provide an effective antiseptic, anti-inflammatory and analgesic treatment. Detailed description of the invention
This invention is related to a pharmaceutical product that contains a local anesthetic called lidocaine or its salts, which relieves pain and irritation; and nonsteroidal anti-inflammatory agent called benzydamine or its salts in anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth; and an antiseptic called cetylpyridinium chloride, which kills bacteria and helps prevent infection.
A preferred embodiment according to the present invention relates to a pharmaceutical composition, characterized in that it comprises:
a) active ingredient selected from nonsteroidal anti-inflammatory agents is benzydamine hydrochloride,
b) active ingredient selected from quaternary ammonium compound of antiseptics is cetylpyridinium chloride,
c) active ingredient selected from local anesthetic agents is lidocaine,
d) optionally a zinc salt,
in combination with at least one pharmaceutically acceptable excipient.
Benzydamine may be used as a pharmaceutically acceptable salt thereof, for example benzydamine hydrochloride.
Cetylpyridinium may be used as a pharmaceutically acceptable salt thereof, for example cetylpyridinium chloride.
In this invention, the term " zinc" means a compound including, but not limited to; zinc,zinc acetate, zinc bromide, zinc caprylate, zinc carbonate, zinc chloride, zinc citrate, zinc formate, zinc hexafluorosilicate, zinc iodate, zinc iodide, zinc iodide-starch, zinc lactate, zinc nitrate, zinc oleate, zinc oxalate, zinc oxide, calamine (zinc oxide with a small proportion of ferric oxide), zinc p-phenolsulfonate, zinc propionate, zinc salicylate, zinc silicate, zinc stearate, zinc sulfate, zinc sulfide, zinc tarmate, zinc tartrate, zinc valerate, zinc ethylenebis(dithiocarbamate), poly(zinc acryfate) or a combination thereof and their pharmaceutically acceptable salts.
The formulation according to the present invention may be in the form of lozenge and other solid oral dosage forms or liquid oral dosage forms. The preferred dosage form according to the present invention is the solid dosage form, preferably a tablet or lozenge form.
Lozenges are the most commonly used OTC products for the treatment of sore throat pain. There are 3 main types: lozenges with a weak topical anesthetic, lozenges with menthol, and unmeditated lozenges.
Pharmaceutical composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s). Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, binders, lubricants, glidants, sweeteners, aromatic agents, preservatives, coloring agents, and the mixtures thereof, to facilitate the physical formulation of various dosage forms like orally disintegrating tablets, chewable tablets and suspensions (including dry powders or granules for suspension).
A preferred embodiment according to the present invention provides a method for preparing pharmaceutical granules in wet granulation, comprising the steps of
a. Benzydamine hydrochloride, an quaternary ammonium compound of antiseptics, a local anesthetic agent, optionally a zinc salt and excipients are mixed with a binder solution comprising PVP, ethanol or water or a combination thereof,
b. after wet granulation process, next steps are fluid bed drying, sieving and finally blend is obtained,
c. obtained blend is mixed with sweetener or flavour agents,
d. lubricating the final blend of step c,
e. compressing the mixture into tablets.
A further preferred embodiment according to the present invention provides a method for preparing pharmaceutical granules in wet granulation, comprising the steps of
a. benzydamine HCI, cetylpyridinium chloride, lidocaine and optionally a zinc salt and excipients are mixed with a binder solution comprising PVP, ethanol or water or a combination thereof, b. after wet granulation process, next steps are fluid bed drying, sieving and finally blend is obtained,
c. obtained blend is mixed with sweetener or flavour agents,
d. lubricating the final blend of step c,
e. compressing the mixture into tablets.
Compositions of this invention may be used in therapy or as a prophylatic against microbial infections accompanied by irritation, such as skin infections. In particular, composition can be used for oral application: as an antiseptic, anti-inflammatory and analgesic treatment of gums, mouth and throat, especially for treatment of plaque, gingivitis and periodontitis, denture irritation. It is useful for treating sore or bacteria infected throat, cough-irritated sore throat, and other oral ailments wherein the source of irritation is partly or wholly derived from microbial infection. It may be used for painful inflammatory conditions of the mouth and throat including pharyngitis (eg following tonsillectomy), aphthous ulcers, aspecific odontostomatoligic affections, glossitis and stomatitis, and teeting troubles, pain and may be used before and/or after dental extractions.
Examples
The manufacturing method of Examples 1 and 2 are described below:
1. Intra-granular powders are weighed and mixed, and optionally a zinc salt is added in a pharmaceutically effective amount.
2. Binder solution is prepared by adding PVP K30 to water, 3. Dry mix of Step 1 is granulated with binder of step 2 and granules are dried.
4. Then dried granules are shifted through 1.0 mm mesh.
5. According to yield, extragranular materials are weighed and shifted and added to dried shifted granules and blended for 5 min.
6. Then lubricant is weighed and shifted and added to above step and lubricated for 3 min and finally resulting powder is compressed.
Figure imgf000007_0001

Claims

1. A pharmaceutical composition, characterized in that it comprises:
a) Benzydamine or pharmaceutical acceptable salt thereof as nonsteroidal antiinflammatory agent,
b) a quaternary ammonium compound of antiseptic,
c) a local anesthetic agent,
d) optionally a zinc salt,
in combination with at least one pharmaceutically acceptable excipient.
2. A pharmaceutical composition according to claim 1, wherein the nonsteroidal anti- inflammatory drug is benzydamine hydrochloride.
3. A pharmaceutical composition according to claims 1-2, wherein quaternary ammonium compound of antiseptic drug is cetylpyridinium and/or pharmaceutically acceptable salts thereof.
4. A pharmaceutical composition according to claim 3, wherein quaternary ammonium compound of antiseptic drug is cetylpyridinium chloride.
5. A pharmaceutical composition according to claims 1-4, wherein local anesthetic drug is lidocaine and/or pharmaceutically acceptable salts thereof.
6. A pharmaceutical composition according to claim 5, wherein local anesthetic drug is lidocaine hydrochloride.
7. A pharmaceutical composition according to any one of the preceeding claims, wherein the pharmaceutical composition is solid dosage form.
8. A pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is tablet or lozenge.
9. A pharmaceutical composition according to any one of the preceeding claims, wherein the pharmaceutical composition is prepared by wet granulation.
10. A pharmaceutical composition according to any one of the preceeding claims, wherein all active ingredients are in the internal phase of composition.
11. A pharmaceutical composition according to any one of the preceeding claims, for use in the treatment of mouth ulcers and sore throats.
PCT/TR2015/000038 2015-02-03 2015-02-03 Stable pharmaceutical combination containing benzydamine WO2016126217A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000038 WO2016126217A1 (en) 2015-02-03 2015-02-03 Stable pharmaceutical combination containing benzydamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000038 WO2016126217A1 (en) 2015-02-03 2015-02-03 Stable pharmaceutical combination containing benzydamine

Publications (1)

Publication Number Publication Date
WO2016126217A1 true WO2016126217A1 (en) 2016-08-11

Family

ID=52697512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2015/000038 WO2016126217A1 (en) 2015-02-03 2015-02-03 Stable pharmaceutical combination containing benzydamine

Country Status (1)

Country Link
WO (1) WO2016126217A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741388C1 (en) * 2020-08-06 2021-01-25 Закрытое акционерное общество "АФОФАРМ" (ЗАО "АФОФАРМ") Medicinal preparation in the form of tablets for prevention and / or treatment of catarrhal, acute respiratory and other infectious-inflammatory diseases of throat and oral cavity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318905A (en) 1963-08-09 1967-05-09 Acraf 1-substituted 3-dialkylaminoalkoxy-in-dazoles and 1-substituted-3-hydroxyindazoles
EP0759739A1 (en) 1994-05-10 1997-03-05 Whitehill Oral Technologies Inc. Improvements in dental floss
EP0812193A1 (en) 1995-02-28 1997-12-17 Smithkline Beecham Farmaceutici S.p.A. Pharmaceutical compositions containing a benzydamine or its salt and an antimicrobial agent
WO2003089007A1 (en) * 2002-04-22 2003-10-30 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
WO2009106963A2 (en) * 2008-02-26 2009-09-03 Italmed S.R.L. Dental composition for preventing and treating stomatitis and mouth ulcers
WO2010020772A2 (en) * 2008-08-22 2010-02-25 Reckitt Benckiser Healthcare (Uk) Limited Improvements in or relating to compositions
EP2570123A1 (en) 2007-11-15 2013-03-20 Reckitt Benckiser Healthcare (UK) Limited Use of 2,4-dichlorobenzyl alcohol having an anaesthetic effect

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318905A (en) 1963-08-09 1967-05-09 Acraf 1-substituted 3-dialkylaminoalkoxy-in-dazoles and 1-substituted-3-hydroxyindazoles
EP0759739A1 (en) 1994-05-10 1997-03-05 Whitehill Oral Technologies Inc. Improvements in dental floss
EP0812193A1 (en) 1995-02-28 1997-12-17 Smithkline Beecham Farmaceutici S.p.A. Pharmaceutical compositions containing a benzydamine or its salt and an antimicrobial agent
EP0812193B1 (en) * 1995-02-28 2002-10-16 GlaxoSmithKline S.p.A. Pharmaceutical compositions containing a benzydamine or its salt and an antimicrobial agent
WO2003089007A1 (en) * 2002-04-22 2003-10-30 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
EP2570123A1 (en) 2007-11-15 2013-03-20 Reckitt Benckiser Healthcare (UK) Limited Use of 2,4-dichlorobenzyl alcohol having an anaesthetic effect
WO2009106963A2 (en) * 2008-02-26 2009-09-03 Italmed S.R.L. Dental composition for preventing and treating stomatitis and mouth ulcers
WO2010020772A2 (en) * 2008-08-22 2010-02-25 Reckitt Benckiser Healthcare (Uk) Limited Improvements in or relating to compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARRER F: "Sprays and lozenges for sore throats", SA (SOUTH AFRICAN) PHARMACEUTICAL JOURNAL, PHARMACEUTICAL SOCIETY OF SOUTH AFRICA, SA, vol. 78, no. 4, 1 January 2011 (2011-01-01), pages 26 - 31, XP009170723, ISSN: 1015-1362 *
GALEOTTI N ET AL: "Local anaesthetic activity of (+)-and (-)-menthol", MEDICINAL & AROMATIC PLANTS ABSTRACTS, SCIENTIFIC PUBLISHERS, SCIENTIFIC PUBLISHERS, NEW DELHI - INDIA, vol. 23, no. 6, 1 December 2001 (2001-12-01), XP018012301, ISSN: 0250-4367 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741388C1 (en) * 2020-08-06 2021-01-25 Закрытое акционерное общество "АФОФАРМ" (ЗАО "АФОФАРМ") Medicinal preparation in the form of tablets for prevention and / or treatment of catarrhal, acute respiratory and other infectious-inflammatory diseases of throat and oral cavity

Similar Documents

Publication Publication Date Title
ES2323395T3 (en) PROCEDURE AND COMPOSITION FOR THE TREATMENT OF IRRITATIONS AND EPIDERMAL INFECTIONS.
US5639795A (en) Liquid polymer composition, and method of use
EP0404558B1 (en) Liquid polymer composition, and method of use
US10568966B2 (en) Formulation for topical wound treatment
CA2900379C (en) Oral antiseptic composition for the treatment of oral mucositis.
JP5740393B2 (en) Composition suitable for topical treatment of fungal infections of the skin and nails
CA2850908C (en) Aqueous antimicrobial composition containing coniferous resin acids
Farrer Sprays and lozenges for sore throats
ES2834985T3 (en) Composition containing cineole for nasal administration
EP3413869B1 (en) Antimicrobial and cleansing composition consisting of a polymeric biguanide and edta
US20060105057A1 (en) Compositions using tetrasilver tetroxide and methods for management of skin conditions using same
WO2003089007B1 (en) Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
WO2016126217A1 (en) Stable pharmaceutical combination containing benzydamine
ES2957220T3 (en) Pharmaceutical preparation and its use in the treatment of viral laryngitis
JPH11228387A (en) Medicinal composition containing iodine-based antimicrobial agent
PL189398B1 (en) Application of dichlorobenzyl alcohol in production of preparations useful in locally treating inflammatory states as well as preparation useful in loacally treating inflammatory states as well as preparation containing such alcohol
US20170027881A1 (en) Composition and related methods for treatment of pilosebaceous diseases
RU2107502C1 (en) Iodine monochloride, veterinary preparation possessing wide range of action
Boddu et al. Excipients and non-medicinal agents as active pharmaceutical ingredients
EP1429815A1 (en) Mixture for use as a protective dressing
US20230099068A1 (en) Topical antimicrobial formulations
JP2018048155A (en) Oral antiseptic composition for treating oral mucositis
Farrer Sprays and lozenges for sore throats: ear, nose and throat
JPS6029684B2 (en) Animal tinea treatment agent
RO127726B1 (en) Pharmaceutical bioadhesive gel-type preparations based on chlorhexidine metal complexes and process for preparing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15711328

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2017/10981

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15711328

Country of ref document: EP

Kind code of ref document: A1